J
Jesse M. Damsker
Researcher at National Institutes of Health
Publications - 41
Citations - 1719
Jesse M. Damsker is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Duchenne muscular dystrophy & Inflammation. The author has an hindex of 20, co-authored 39 publications receiving 1447 citations. Previous affiliations of Jesse M. Damsker include George Washington University & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Lung inflammation, injury, and proliferative response after repetitive particulate hexavalent chromium exposure
Laura M. Beaver,Erik J. Stemmy,Arnold M. Schwartz,Jesse M. Damsker,Stephanie L. Constant,Susan Ceryak,Steven R. Patierno +6 more
TL;DR: It is illustrated that repetitive exposure to particulate chromate induces chronic injury and an inflammatory microenvironment that may promote Cr(VI) carcinogenesis.
Journal ArticleDOI
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
Laurie S. Conklin,Jesse M. Damsker,Eric P. Hoffman,William J. Jusko,Panteleimon D. Mavroudis,Benjamin D Schwartz,Laurel J Mengle-Gaw,Edward C. Smith,Jean K. Mah,Michela Guglieri,Yoram Nevo,Nancy L. Kuntz,Craig M. McDonald,Mar Tulinius,Monique M. Ryan,Richard Webster,Diana Castro,Richard S. Finkel,Andrea L. Smith,Lauren P. Morgenroth,Antonio Arrieta,Maya Shimony,Mark Jaros,Phil Shale,John M. McCall,Yetrib Hathout,Kanneboyina Nagaraju,John N. van den Anker,Leanne M Ward,Alexandra Ahmet,Michaelyn R. Cornish,Paula R. Clemens +31 more
TL;DR: The development of the first dissociative steroid that preserves anti‐inflammatory efficacy and decreases steroid‐associated safety concerns is demonstrated, with an array of pre‐selected biomarkers in multiple contexts of use.
Journal ArticleDOI
Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy.
Eric P. Hoffman,Erica K.M. Reeves,Jesse M. Damsker,Kanneboyina Nagaraju,John M. McCall,Edward M. Connor,Kate Bushby +6 more
TL;DR: A new trial, FOR-DMD, aims to address a gap in knowledge in the area of "dissociative steroids," drugs that are able to better separate efficacy and side effects, providing a broader therapeutic window.
Journal ArticleDOI
Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
Eric P. Hoffman,Benjamin D Schwartz,Laurel J Mengle-Gaw,Edward C. Smith,Diana Castro,Jean K. Mah,Craig M. McDonald,Nancy L. Kuntz,Richard S. Finkel,Michela Guglieri,Katharine Bushby,Mar Tulinius,Yoram Nevo,Monique M. Ryan,Richard D. Webster,Andrea L. Smith,Lauren P. Morgenroth,Antonio Arrieta,Maya Shimony,Catherine Siener,Mark Jaros,Phil Shale,John M. McCall,Kanneboyina Nagaraju,John N. van den Anker,Laurie S. Conklin,Avital Cnaan,Heather Gordish-Dressman,Jesse M. Damsker,Paula R. Clemens +29 more
TL;DR: This study provides Class IV evidence that for boys with DMD, vamorolone demonstrated possible efficacy compared to a natural history cohort of glucocorticoid-naive patients and appeared to be tolerated.
Journal ArticleDOI
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
Erica K.M. Reeves,Eric P. Hoffman,Eric P. Hoffman,Kanneboyina Nagaraju,Kanneboyina Nagaraju,Jesse M. Damsker,John M. McCall +6 more
TL;DR: It was concluded that Δ9,11 steroids showed novel anti-inflammatory properties, retaining NF-κB inhibition, but losing deleterious glucocorticoid side effect profiles.